nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyproheptadine—Photosensitivity—Vemurafenib—melanoma	0.00879	0.0256	CcSEcCtD
Cyproheptadine—Chest tightness—Docetaxel—melanoma	0.00771	0.0225	CcSEcCtD
Cyproheptadine—Cholestasis—Temozolomide—melanoma	0.00716	0.0209	CcSEcCtD
Cyproheptadine—Wheezing—Bleomycin—melanoma	0.00626	0.0182	CcSEcCtD
Cyproheptadine—Photosensitivity reaction—Vemurafenib—melanoma	0.00609	0.0177	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Vemurafenib—melanoma	0.00583	0.017	CcSEcCtD
Cyproheptadine—Hepatic failure—Dactinomycin—melanoma	0.00485	0.0141	CcSEcCtD
Cyproheptadine—Neuritis—Docetaxel—melanoma	0.00484	0.0141	CcSEcCtD
Cyproheptadine—Chills—Vemurafenib—melanoma	0.00479	0.014	CcSEcCtD
Cyproheptadine—Hepatic failure—Temozolomide—melanoma	0.00439	0.0128	CcSEcCtD
Cyproheptadine—Nasal congestion—Temozolomide—melanoma	0.00433	0.0126	CcSEcCtD
Cyproheptadine—Chest discomfort—Docetaxel—melanoma	0.00409	0.0119	CcSEcCtD
Cyproheptadine—Diplopia—Carmustine—melanoma	0.00408	0.0119	CcSEcCtD
Cyproheptadine—Diplopia—Temozolomide—melanoma	0.00395	0.0115	CcSEcCtD
Cyproheptadine—Hypotension—Vemurafenib—melanoma	0.00355	0.0103	CcSEcCtD
Cyproheptadine—Sweating increased—Temozolomide—melanoma	0.00332	0.00968	CcSEcCtD
Cyproheptadine—Decreased appetite—Vemurafenib—melanoma	0.0033	0.00961	CcSEcCtD
Cyproheptadine—Fatigue—Vemurafenib—melanoma	0.00327	0.00953	CcSEcCtD
Cyproheptadine—Constipation—Vemurafenib—melanoma	0.00324	0.00945	CcSEcCtD
Cyproheptadine—Pollakiuria—Temozolomide—melanoma	0.00315	0.00918	CcSEcCtD
Cyproheptadine—Agranulocytosis—Dactinomycin—melanoma	0.00314	0.00914	CcSEcCtD
Cyproheptadine—Photosensitivity reaction—Temozolomide—melanoma	0.00311	0.00907	CcSEcCtD
Cyproheptadine—Weight increased—Temozolomide—melanoma	0.0031	0.00904	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Carmustine—melanoma	0.00308	0.00898	CcSEcCtD
Cyproheptadine—Hepatitis—Dactinomycin—melanoma	0.00302	0.00879	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Temozolomide—melanoma	0.00298	0.00868	CcSEcCtD
Cyproheptadine—Hepatic failure—Docetaxel—melanoma	0.00292	0.00851	CcSEcCtD
Cyproheptadine—Chills—Bleomycin—melanoma	0.0029	0.00846	CcSEcCtD
Cyproheptadine—Hallucination—Carmustine—melanoma	0.00281	0.00819	CcSEcCtD
Cyproheptadine—Hepatitis—Temozolomide—melanoma	0.00273	0.00795	CcSEcCtD
Cyproheptadine—Asthenia—Vemurafenib—melanoma	0.00272	0.00793	CcSEcCtD
Cyproheptadine—Hallucination—Temozolomide—melanoma	0.00272	0.00791	CcSEcCtD
Cyproheptadine—Chills—Dactinomycin—melanoma	0.00271	0.00789	CcSEcCtD
Cyproheptadine—Diarrhoea—Vemurafenib—melanoma	0.0026	0.00756	CcSEcCtD
Cyproheptadine—Tinnitus—Temozolomide—melanoma	0.00254	0.00741	CcSEcCtD
Cyproheptadine—Leukopenia—Bleomycin—melanoma	0.00252	0.00734	CcSEcCtD
Cyproheptadine—Dizziness—Vemurafenib—melanoma	0.00251	0.00731	CcSEcCtD
Cyproheptadine—Chills—Temozolomide—melanoma	0.00245	0.00713	CcSEcCtD
Cyproheptadine—Vomiting—Vemurafenib—melanoma	0.00241	0.00703	CcSEcCtD
Cyproheptadine—Rash—Vemurafenib—melanoma	0.00239	0.00697	CcSEcCtD
Cyproheptadine—Dermatitis—Vemurafenib—melanoma	0.00239	0.00696	CcSEcCtD
Cyproheptadine—Headache—Vemurafenib—melanoma	0.00238	0.00692	CcSEcCtD
Cyproheptadine—Leukopenia—Dactinomycin—melanoma	0.00235	0.00685	CcSEcCtD
Cyproheptadine—Confusional state—Bleomycin—melanoma	0.00232	0.00675	CcSEcCtD
Cyproheptadine—Vision blurred—Carmustine—melanoma	0.00232	0.00675	CcSEcCtD
Cyproheptadine—Tremor—Carmustine—melanoma	0.0023	0.00671	CcSEcCtD
Cyproheptadine—Oedema—Bleomycin—melanoma	0.0023	0.0067	CcSEcCtD
Cyproheptadine—Agitation—Carmustine—melanoma	0.00226	0.00658	CcSEcCtD
Cyproheptadine—Nausea—Vemurafenib—melanoma	0.00225	0.00657	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Bleomycin—melanoma	0.00225	0.00656	CcSEcCtD
Cyproheptadine—Vision blurred—Temozolomide—melanoma	0.00224	0.00652	CcSEcCtD
Cyproheptadine—Tremor—Temozolomide—melanoma	0.00223	0.00648	CcSEcCtD
Cyproheptadine—Leukopenia—Carmustine—melanoma	0.0022	0.00641	CcSEcCtD
Cyproheptadine—Anorexia—Bleomycin—melanoma	0.00219	0.00638	CcSEcCtD
Cyproheptadine—Agitation—Temozolomide—melanoma	0.00218	0.00636	CcSEcCtD
Cyproheptadine—Hypotension—Bleomycin—melanoma	0.00215	0.00626	CcSEcCtD
Cyproheptadine—Oedema—Dactinomycin—melanoma	0.00214	0.00625	CcSEcCtD
Cyproheptadine—Vertigo—Temozolomide—melanoma	0.00213	0.00622	CcSEcCtD
Cyproheptadine—Convulsion—Carmustine—melanoma	0.00213	0.00621	CcSEcCtD
Cyproheptadine—Leukopenia—Temozolomide—melanoma	0.00213	0.0062	CcSEcCtD
Cyproheptadine—Palpitations—Temozolomide—melanoma	0.0021	0.00612	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Dactinomycin—melanoma	0.0021	0.00612	CcSEcCtD
Cyproheptadine—Paraesthesia—Bleomycin—melanoma	0.00206	0.00601	CcSEcCtD
Cyproheptadine—Weight increased—Docetaxel—melanoma	0.00206	0.00601	CcSEcCtD
Cyproheptadine—Convulsion—Temozolomide—melanoma	0.00206	0.006	CcSEcCtD
Cyproheptadine—Anorexia—Dactinomycin—melanoma	0.00204	0.00595	CcSEcCtD
Cyproheptadine—Confusional state—Carmustine—melanoma	0.00202	0.00589	CcSEcCtD
Cyproheptadine—Oedema—Carmustine—melanoma	0.00201	0.00585	CcSEcCtD
Cyproheptadine—Decreased appetite—Bleomycin—melanoma	0.002	0.00582	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Docetaxel—melanoma	0.00198	0.00577	CcSEcCtD
Cyproheptadine—Jaundice—Docetaxel—melanoma	0.00197	0.00574	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Carmustine—melanoma	0.00196	0.00572	CcSEcCtD
Cyproheptadine—Tachycardia—Carmustine—melanoma	0.00196	0.00571	CcSEcCtD
Cyproheptadine—Confusional state—Temozolomide—melanoma	0.00196	0.0057	CcSEcCtD
Cyproheptadine—Oedema—Temozolomide—melanoma	0.00194	0.00565	CcSEcCtD
Cyproheptadine—Anorexia—Carmustine—melanoma	0.00191	0.00557	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Temozolomide—melanoma	0.0019	0.00553	CcSEcCtD
Cyproheptadine—Feeling abnormal—Bleomycin—melanoma	0.00189	0.00552	CcSEcCtD
Cyproheptadine—Agranulocytosis—Docetaxel—melanoma	0.00189	0.0055	CcSEcCtD
Cyproheptadine—Hypotension—Carmustine—melanoma	0.00188	0.00546	CcSEcCtD
Cyproheptadine—Hyperhidrosis—Temozolomide—melanoma	0.00187	0.00546	CcSEcCtD
Cyproheptadine—Decreased appetite—Dactinomycin—melanoma	0.00186	0.00543	CcSEcCtD
Cyproheptadine—Fatigue—Dactinomycin—melanoma	0.00185	0.00538	CcSEcCtD
Cyproheptadine—Anorexia—Temozolomide—melanoma	0.00185	0.00538	CcSEcCtD
Cyproheptadine—Urticaria—Bleomycin—melanoma	0.00183	0.00532	CcSEcCtD
Cyproheptadine—Hepatitis—Docetaxel—melanoma	0.00182	0.00529	CcSEcCtD
Cyproheptadine—Insomnia—Carmustine—melanoma	0.00181	0.00529	CcSEcCtD
Cyproheptadine—Paraesthesia—Carmustine—melanoma	0.0018	0.00525	CcSEcCtD
Cyproheptadine—Somnolence—Carmustine—melanoma	0.00178	0.0052	CcSEcCtD
Cyproheptadine—Feeling abnormal—Dactinomycin—melanoma	0.00177	0.00515	CcSEcCtD
Cyproheptadine—Insomnia—Temozolomide—melanoma	0.00175	0.00511	CcSEcCtD
Cyproheptadine—Decreased appetite—Carmustine—melanoma	0.00174	0.00508	CcSEcCtD
Cyproheptadine—Paraesthesia—Temozolomide—melanoma	0.00174	0.00507	CcSEcCtD
Cyproheptadine—Somnolence—Temozolomide—melanoma	0.00172	0.00502	CcSEcCtD
Cyproheptadine—Constipation—Carmustine—melanoma	0.00172	0.005	CcSEcCtD
Cyproheptadine—Dyspepsia—Temozolomide—melanoma	0.00171	0.00497	CcSEcCtD
Cyproheptadine—Decreased appetite—Temozolomide—melanoma	0.00169	0.00491	CcSEcCtD
Cyproheptadine—Fatigue—Temozolomide—melanoma	0.00167	0.00487	CcSEcCtD
Cyproheptadine—Constipation—Temozolomide—melanoma	0.00166	0.00483	CcSEcCtD
Cyproheptadine—Feeling abnormal—Carmustine—melanoma	0.00165	0.00482	CcSEcCtD
Cyproheptadine—Asthenia—Bleomycin—melanoma	0.00165	0.0048	CcSEcCtD
Cyproheptadine—Chills—Docetaxel—melanoma	0.00163	0.00474	CcSEcCtD
Cyproheptadine—Feeling abnormal—Temozolomide—melanoma	0.0016	0.00466	CcSEcCtD
Cyproheptadine—Urticaria—Temozolomide—melanoma	0.00154	0.00449	CcSEcCtD
Cyproheptadine—Asthenia—Dactinomycin—melanoma	0.00154	0.00448	CcSEcCtD
Cyproheptadine—Diarrhoea—Dactinomycin—melanoma	0.00147	0.00427	CcSEcCtD
Cyproheptadine—Vomiting—Bleomycin—melanoma	0.00146	0.00426	CcSEcCtD
Cyproheptadine—Rash—Bleomycin—melanoma	0.00145	0.00422	CcSEcCtD
Cyproheptadine—Dermatitis—Bleomycin—melanoma	0.00145	0.00422	CcSEcCtD
Cyproheptadine—Asthenia—Carmustine—melanoma	0.00144	0.00419	CcSEcCtD
Cyproheptadine—Syncope—Docetaxel—melanoma	0.00142	0.00413	CcSEcCtD
Cyproheptadine—Leukopenia—Docetaxel—melanoma	0.00141	0.00412	CcSEcCtD
Cyproheptadine—Palpitations—Docetaxel—melanoma	0.0014	0.00407	CcSEcCtD
Cyproheptadine—Asthenia—Temozolomide—melanoma	0.00139	0.00405	CcSEcCtD
Cyproheptadine—Loss of consciousness—Docetaxel—melanoma	0.00139	0.00405	CcSEcCtD
Cyproheptadine—Diarrhoea—Carmustine—melanoma	0.00137	0.004	CcSEcCtD
Cyproheptadine—Convulsion—Docetaxel—melanoma	0.00137	0.00399	CcSEcCtD
Cyproheptadine—Nausea—Bleomycin—melanoma	0.00137	0.00398	CcSEcCtD
Cyproheptadine—Vomiting—Dactinomycin—melanoma	0.00136	0.00397	CcSEcCtD
Cyproheptadine—Rash—Dactinomycin—melanoma	0.00135	0.00394	CcSEcCtD
Cyproheptadine—Dizziness—Carmustine—melanoma	0.00133	0.00387	CcSEcCtD
Cyproheptadine—Diarrhoea—Temozolomide—melanoma	0.00133	0.00387	CcSEcCtD
Cyproheptadine—Confusional state—Docetaxel—melanoma	0.0013	0.00379	CcSEcCtD
Cyproheptadine—Oedema—Docetaxel—melanoma	0.00129	0.00376	CcSEcCtD
Cyproheptadine—Dizziness—Temozolomide—melanoma	0.00128	0.00374	CcSEcCtD
Cyproheptadine—Vomiting—Carmustine—melanoma	0.00128	0.00372	CcSEcCtD
Cyproheptadine—Nausea—Dactinomycin—melanoma	0.00127	0.00371	CcSEcCtD
Cyproheptadine—Shock—Docetaxel—melanoma	0.00127	0.0037	CcSEcCtD
Cyproheptadine—Rash—Carmustine—melanoma	0.00127	0.00369	CcSEcCtD
Cyproheptadine—Dermatitis—Carmustine—melanoma	0.00126	0.00368	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Docetaxel—melanoma	0.00126	0.00368	CcSEcCtD
Cyproheptadine—Tachycardia—Docetaxel—melanoma	0.00126	0.00367	CcSEcCtD
Cyproheptadine—Headache—Carmustine—melanoma	0.00126	0.00366	CcSEcCtD
Cyproheptadine—Vomiting—Temozolomide—melanoma	0.00123	0.00359	CcSEcCtD
Cyproheptadine—Anorexia—Docetaxel—melanoma	0.00123	0.00358	CcSEcCtD
Cyproheptadine—Rash—Temozolomide—melanoma	0.00122	0.00356	CcSEcCtD
Cyproheptadine—Dermatitis—Temozolomide—melanoma	0.00122	0.00356	CcSEcCtD
Cyproheptadine—Headache—Temozolomide—melanoma	0.00121	0.00354	CcSEcCtD
Cyproheptadine—Hypotension—Docetaxel—melanoma	0.00121	0.00351	CcSEcCtD
Cyproheptadine—Nausea—Carmustine—melanoma	0.00119	0.00347	CcSEcCtD
Cyproheptadine—Insomnia—Docetaxel—melanoma	0.00117	0.0034	CcSEcCtD
Cyproheptadine—Paraesthesia—Docetaxel—melanoma	0.00116	0.00337	CcSEcCtD
Cyproheptadine—Nausea—Temozolomide—melanoma	0.00115	0.00336	CcSEcCtD
Cyproheptadine—Somnolence—Docetaxel—melanoma	0.00115	0.00334	CcSEcCtD
Cyproheptadine—Dyspepsia—Docetaxel—melanoma	0.00114	0.00331	CcSEcCtD
Cyproheptadine—Decreased appetite—Docetaxel—melanoma	0.00112	0.00327	CcSEcCtD
Cyproheptadine—Fatigue—Docetaxel—melanoma	0.00111	0.00324	CcSEcCtD
Cyproheptadine—Constipation—Docetaxel—melanoma	0.0011	0.00321	CcSEcCtD
Cyproheptadine—Feeling abnormal—Docetaxel—melanoma	0.00106	0.0031	CcSEcCtD
Cyproheptadine—Asthenia—Docetaxel—melanoma	0.000925	0.0027	CcSEcCtD
Cyproheptadine—Diarrhoea—Docetaxel—melanoma	0.000882	0.00257	CcSEcCtD
Cyproheptadine—Dizziness—Docetaxel—melanoma	0.000853	0.00248	CcSEcCtD
Cyproheptadine—Vomiting—Docetaxel—melanoma	0.00082	0.00239	CcSEcCtD
Cyproheptadine—Rash—Docetaxel—melanoma	0.000813	0.00237	CcSEcCtD
Cyproheptadine—Dermatitis—Docetaxel—melanoma	0.000812	0.00237	CcSEcCtD
Cyproheptadine—Headache—Docetaxel—melanoma	0.000808	0.00235	CcSEcCtD
Cyproheptadine—Nausea—Docetaxel—melanoma	0.000766	0.00223	CcSEcCtD
Cyproheptadine—Protriptyline—ABCB1—melanoma	0.000151	0.271	CrCbGaD
Cyproheptadine—Clozapine—CYP1B1—melanoma	0.00015	0.27	CrCbGaD
Cyproheptadine—Carbamazepine—ABCB1—melanoma	7.01e-05	0.126	CrCbGaD
Cyproheptadine—Nortriptyline—ALB—melanoma	6.05e-05	0.109	CrCbGaD
Cyproheptadine—Clozapine—ABCB1—melanoma	4.31e-05	0.0774	CrCbGaD
Cyproheptadine—Amitriptyline—ALB—melanoma	4.2e-05	0.0754	CrCbGaD
Cyproheptadine—Amitriptyline—ABCB1—melanoma	4e-05	0.072	CrCbGaD
Cyproheptadine—HTR1A—Signaling Pathways—IL2—melanoma	2.76e-05	4.2e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—CASP3—melanoma	2.75e-05	4.18e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling by GPCR—IL6—melanoma	2.74e-05	4.18e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—IL2—melanoma	2.74e-05	4.18e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—MAPK3—melanoma	2.73e-05	4.16e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling by GPCR—IL6—melanoma	2.73e-05	4.16e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling by GPCR—PIK3CA—melanoma	2.72e-05	4.14e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—MDM2—melanoma	2.71e-05	4.13e-05	CbGpPWpGaD
Cyproheptadine—HTR6—Signaling Pathways—KRAS—melanoma	2.69e-05	4.1e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—CCND1—melanoma	2.69e-05	4.09e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling by GPCR—PIK3CA—melanoma	2.68e-05	4.08e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—CCND1—melanoma	2.67e-05	4.07e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—ERBB2—melanoma	2.67e-05	4.07e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling by GPCR—PIK3CA—melanoma	2.67e-05	4.07e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—MDM2—melanoma	2.66e-05	4.06e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling by GPCR—PIK3CA—melanoma	2.66e-05	4.05e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—CTNNB1—melanoma	2.66e-05	4.05e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—MDM2—melanoma	2.66e-05	4.05e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—MYC—melanoma	2.66e-05	4.05e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Metabolism—PTEN—melanoma	2.66e-05	4.05e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling by GPCR—PIK3CA—melanoma	2.65e-05	4.04e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—MDM2—melanoma	2.65e-05	4.04e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—CTNNB1—melanoma	2.65e-05	4.03e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—MDM2—melanoma	2.64e-05	4.03e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—PIK3CB—melanoma	2.63e-05	4.02e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—ERBB2—melanoma	2.63e-05	4e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling by GPCR—PIK3CA—melanoma	2.63e-05	4e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—ERBB2—melanoma	2.62e-05	3.99e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—MDM2—melanoma	2.62e-05	3.99e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—ERBB2—melanoma	2.61e-05	3.98e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—MMP9—melanoma	2.61e-05	3.97e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—ERBB2—melanoma	2.6e-05	3.97e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—MAPK1—melanoma	2.6e-05	3.96e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—EGFR—melanoma	2.6e-05	3.96e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—CDKN1A—melanoma	2.6e-05	3.96e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—MMP9—melanoma	2.59e-05	3.95e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—PTEN—melanoma	2.59e-05	3.95e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—PIK3CB—melanoma	2.59e-05	3.95e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—PIK3CB—melanoma	2.59e-05	3.94e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—CDKN1A—melanoma	2.59e-05	3.94e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—NFKB1—melanoma	2.58e-05	3.93e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—PTEN—melanoma	2.58e-05	3.93e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—ERBB2—melanoma	2.58e-05	3.93e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—PIK3CB—melanoma	2.58e-05	3.93e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—PIK3CB—melanoma	2.57e-05	3.92e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—NFKB1—melanoma	2.57e-05	3.91e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—PIK3CB—melanoma	2.55e-05	3.88e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—CXCL8—melanoma	2.53e-05	3.86e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling by GPCR—AKT1—melanoma	2.53e-05	3.86e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling by GPCR—AKT1—melanoma	2.52e-05	3.84e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling by GPCR—HRAS—melanoma	2.52e-05	3.83e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—CXCL8—melanoma	2.49e-05	3.8e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—CXCL8—melanoma	2.49e-05	3.79e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—CXCL8—melanoma	2.48e-05	3.78e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling by GPCR—HRAS—melanoma	2.47e-05	3.77e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—CDKN1B—melanoma	2.47e-05	3.77e-05	CbGpPWpGaD
Cyproheptadine—HTR6—Signaling Pathways—PIK3CA—melanoma	2.47e-05	3.77e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—CXCL8—melanoma	2.47e-05	3.76e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling by GPCR—HRAS—melanoma	2.47e-05	3.76e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling by GPCR—HRAS—melanoma	2.46e-05	3.75e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—KRAS—melanoma	2.46e-05	3.74e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling by GPCR—HRAS—melanoma	2.45e-05	3.74e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—CXCL8—melanoma	2.45e-05	3.73e-05	CbGpPWpGaD
Cyproheptadine—DRD2—GPCR downstream signaling—AKT1—melanoma	2.45e-05	3.73e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—CDKN1B—melanoma	2.43e-05	3.71e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling by GPCR—HRAS—melanoma	2.43e-05	3.7e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—CDKN1B—melanoma	2.43e-05	3.7e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—CASP3—melanoma	2.42e-05	3.69e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—CDKN1B—melanoma	2.42e-05	3.69e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—IL2—melanoma	2.42e-05	3.69e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—CDKN1B—melanoma	2.41e-05	3.68e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling by GPCR—IL6—melanoma	2.41e-05	3.67e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—GPCR downstream signaling—AKT1—melanoma	2.41e-05	3.67e-05	CbGpPWpGaD
Cyproheptadine—HRH1—GPCR downstream signaling—AKT1—melanoma	2.4e-05	3.66e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—GPCR downstream signaling—AKT1—melanoma	2.39e-05	3.65e-05	CbGpPWpGaD
Cyproheptadine—HTR6—Signaling Pathways—TP53—melanoma	2.39e-05	3.64e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—CDKN1B—melanoma	2.39e-05	3.64e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—GPCR downstream signaling—AKT1—melanoma	2.39e-05	3.64e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—CASP3—melanoma	2.38e-05	3.63e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—IL2—melanoma	2.38e-05	3.63e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—CASP3—melanoma	2.38e-05	3.63e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—IL2—melanoma	2.38e-05	3.62e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—CASP3—melanoma	2.37e-05	3.61e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling by GPCR—IL6—melanoma	2.37e-05	3.61e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—IL2—melanoma	2.37e-05	3.61e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—CASP3—melanoma	2.36e-05	3.6e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling by GPCR—IL6—melanoma	2.36e-05	3.6e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—GPCR downstream signaling—AKT1—melanoma	2.36e-05	3.6e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—IL2—melanoma	2.36e-05	3.6e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—CCND1—melanoma	2.36e-05	3.59e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling by GPCR—IL6—melanoma	2.36e-05	3.59e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling by GPCR—IL6—melanoma	2.35e-05	3.58e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—VEGFA—melanoma	2.34e-05	3.57e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—CASP3—melanoma	2.34e-05	3.57e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—IL2—melanoma	2.34e-05	3.56e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—CTNNB1—melanoma	2.34e-05	3.56e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—VEGFA—melanoma	2.33e-05	3.55e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling by GPCR—IL6—melanoma	2.33e-05	3.54e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—CCND1—melanoma	2.32e-05	3.54e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—STAT3—melanoma	2.32e-05	3.53e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—CCND1—melanoma	2.32e-05	3.53e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—NRAS—melanoma	2.31e-05	3.53e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—CCND1—melanoma	2.31e-05	3.52e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—STAT3—melanoma	2.31e-05	3.52e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—NRAS—melanoma	2.3e-05	3.51e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—CCND1—melanoma	2.3e-05	3.51e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—CTNNB1—melanoma	2.3e-05	3.5e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—CTNNB1—melanoma	2.29e-05	3.49e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—MMP9—melanoma	2.29e-05	3.49e-05	CbGpPWpGaD
Cyproheptadine—HTR6—Signaling Pathways—HRAS—melanoma	2.29e-05	3.48e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—CTNNB1—melanoma	2.29e-05	3.48e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—CDKN1A—melanoma	2.28e-05	3.48e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—CCND1—melanoma	2.28e-05	3.47e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—CTNNB1—melanoma	2.28e-05	3.47e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—PTEN—melanoma	2.28e-05	3.47e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—NFKB1—melanoma	2.27e-05	3.45e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—CTNNB1—melanoma	2.26e-05	3.44e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—PIK3CA—melanoma	2.26e-05	3.44e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—MMP9—melanoma	2.25e-05	3.43e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—MMP9—melanoma	2.25e-05	3.43e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—CDKN1A—melanoma	2.25e-05	3.42e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—MMP9—melanoma	2.24e-05	3.42e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—CDKN1A—melanoma	2.24e-05	3.41e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—PTEN—melanoma	2.24e-05	3.41e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—PTEN—melanoma	2.24e-05	3.41e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—MMP9—melanoma	2.23e-05	3.4e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—CDKN1A—melanoma	2.23e-05	3.4e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—NFKB1—melanoma	2.23e-05	3.4e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—PTEN—melanoma	2.23e-05	3.4e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—CDKN1A—melanoma	2.23e-05	3.39e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—NFKB1—melanoma	2.22e-05	3.39e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling by GPCR—AKT1—melanoma	2.22e-05	3.38e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—PTEN—melanoma	2.22e-05	3.38e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—NFKB1—melanoma	2.22e-05	3.38e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—MAPK3—melanoma	2.22e-05	3.38e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—MMP9—melanoma	2.21e-05	3.37e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—NFKB1—melanoma	2.21e-05	3.37e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—CDKN1A—melanoma	2.2e-05	3.36e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—MAPK3—melanoma	2.2e-05	3.36e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—PTEN—melanoma	2.2e-05	3.35e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—NFKB1—melanoma	2.19e-05	3.34e-05	CbGpPWpGaD
Cyproheptadine—HTR6—Signaling Pathways—IL6—melanoma	2.19e-05	3.33e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling by GPCR—AKT1—melanoma	2.19e-05	3.33e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—TP53—melanoma	2.18e-05	3.33e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling by GPCR—AKT1—melanoma	2.18e-05	3.32e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling by GPCR—AKT1—melanoma	2.17e-05	3.31e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling by GPCR—AKT1—melanoma	2.17e-05	3.3e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—MYC—melanoma	2.15e-05	3.28e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling by GPCR—AKT1—melanoma	2.15e-05	3.27e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—MYC—melanoma	2.14e-05	3.27e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—MAPK1—melanoma	2.11e-05	3.21e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—EGFR—melanoma	2.11e-05	3.21e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—MAPK1—melanoma	2.1e-05	3.2e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—EGFR—melanoma	2.1e-05	3.2e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—HRAS—melanoma	2.09e-05	3.18e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—VEGFA—melanoma	2.06e-05	3.13e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—STAT3—melanoma	2.04e-05	3.1e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—NRAS—melanoma	2.03e-05	3.1e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—VEGFA—melanoma	2.02e-05	3.08e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—VEGFA—melanoma	2.02e-05	3.08e-05	CbGpPWpGaD
Cyproheptadine—HTR6—Signaling Pathways—AKT1—melanoma	2.02e-05	3.08e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—VEGFA—melanoma	2.01e-05	3.07e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—VEGFA—melanoma	2.01e-05	3.06e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—STAT3—melanoma	2e-05	3.05e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—STAT3—melanoma	2e-05	3.05e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—NRAS—melanoma	2e-05	3.05e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—IL6—melanoma	2e-05	3.04e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—NRAS—melanoma	1.99e-05	3.04e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—STAT3—melanoma	1.99e-05	3.04e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—KRAS—melanoma	1.99e-05	3.03e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—NRAS—melanoma	1.99e-05	3.03e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—VEGFA—melanoma	1.99e-05	3.03e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—STAT3—melanoma	1.99e-05	3.03e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—NRAS—melanoma	1.98e-05	3.02e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—KRAS—melanoma	1.98e-05	3.02e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—STAT3—melanoma	1.97e-05	3e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—NRAS—melanoma	1.96e-05	2.99e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—MAPK3—melanoma	1.95e-05	2.96e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—MAPK3—melanoma	1.91e-05	2.92e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—MAPK3—melanoma	1.91e-05	2.91e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—MAPK3—melanoma	1.9e-05	2.9e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—MAPK3—melanoma	1.9e-05	2.89e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—MYC—melanoma	1.89e-05	2.88e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—MAPK3—melanoma	1.88e-05	2.86e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Metabolism—PIK3CA—melanoma	1.87e-05	2.86e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—MYC—melanoma	1.86e-05	2.84e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—MYC—melanoma	1.86e-05	2.83e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—MYC—melanoma	1.85e-05	2.82e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—MAPK1—melanoma	1.85e-05	2.82e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—EGFR—melanoma	1.85e-05	2.82e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—MYC—melanoma	1.85e-05	2.81e-05	CbGpPWpGaD
Cyproheptadine—HTR2B—Signaling Pathways—AKT1—melanoma	1.84e-05	2.81e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—PIK3CA—melanoma	1.83e-05	2.79e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—MYC—melanoma	1.83e-05	2.79e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—MAPK1—melanoma	1.82e-05	2.78e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—EGFR—melanoma	1.82e-05	2.77e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—PIK3CA—melanoma	1.82e-05	2.77e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—MAPK1—melanoma	1.82e-05	2.77e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—EGFR—melanoma	1.82e-05	2.77e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—MAPK1—melanoma	1.81e-05	2.76e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—EGFR—melanoma	1.81e-05	2.76e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—MAPK1—melanoma	1.81e-05	2.75e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—EGFR—melanoma	1.81e-05	2.75e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—MAPK1—melanoma	1.79e-05	2.72e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—EGFR—melanoma	1.79e-05	2.72e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—TP53—melanoma	1.77e-05	2.7e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—TP53—melanoma	1.76e-05	2.68e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—KRAS—melanoma	1.75e-05	2.66e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—KRAS—melanoma	1.72e-05	2.62e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—KRAS—melanoma	1.72e-05	2.62e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—KRAS—melanoma	1.71e-05	2.61e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—KRAS—melanoma	1.71e-05	2.6e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—HRAS—melanoma	1.69e-05	2.58e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—KRAS—melanoma	1.69e-05	2.57e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—HRAS—melanoma	1.68e-05	2.57e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—IL6—melanoma	1.62e-05	2.47e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—IL6—melanoma	1.61e-05	2.46e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—PIK3CA—melanoma	1.61e-05	2.45e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—PIK3CA—melanoma	1.58e-05	2.41e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—PIK3CA—melanoma	1.58e-05	2.4e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—PIK3CA—melanoma	1.57e-05	2.4e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—PIK3CA—melanoma	1.57e-05	2.39e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—TP53—melanoma	1.55e-05	2.37e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—PIK3CA—melanoma	1.55e-05	2.36e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Metabolism—AKT1—melanoma	1.53e-05	2.33e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—TP53—melanoma	1.53e-05	2.33e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—TP53—melanoma	1.53e-05	2.32e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—TP53—melanoma	1.52e-05	2.32e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—TP53—melanoma	1.52e-05	2.31e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—TP53—melanoma	1.5e-05	2.29e-05	CbGpPWpGaD
Cyproheptadine—HTR1A—Signaling Pathways—AKT1—melanoma	1.49e-05	2.28e-05	CbGpPWpGaD
Cyproheptadine—HTR2C—Signaling Pathways—AKT1—melanoma	1.49e-05	2.27e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—HRAS—melanoma	1.49e-05	2.26e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—HRAS—melanoma	1.46e-05	2.23e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—HRAS—melanoma	1.46e-05	2.22e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—HRAS—melanoma	1.45e-05	2.22e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—HRAS—melanoma	1.45e-05	2.21e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—HRAS—melanoma	1.44e-05	2.19e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—IL6—melanoma	1.42e-05	2.17e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—IL6—melanoma	1.4e-05	2.13e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—IL6—melanoma	1.4e-05	2.13e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—IL6—melanoma	1.39e-05	2.12e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—IL6—melanoma	1.39e-05	2.11e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—IL6—melanoma	1.37e-05	2.09e-05	CbGpPWpGaD
Cyproheptadine—DRD2—Signaling Pathways—AKT1—melanoma	1.31e-05	2e-05	CbGpPWpGaD
Cyproheptadine—HTR2A—Signaling Pathways—AKT1—melanoma	1.29e-05	1.97e-05	CbGpPWpGaD
Cyproheptadine—HRH1—Signaling Pathways—AKT1—melanoma	1.29e-05	1.96e-05	CbGpPWpGaD
Cyproheptadine—CHRM1—Signaling Pathways—AKT1—melanoma	1.28e-05	1.96e-05	CbGpPWpGaD
Cyproheptadine—CHRM3—Signaling Pathways—AKT1—melanoma	1.28e-05	1.95e-05	CbGpPWpGaD
Cyproheptadine—CHRM2—Signaling Pathways—AKT1—melanoma	1.27e-05	1.93e-05	CbGpPWpGaD
